Product Description
BMS-986393 is a GPRC5D-directed autologous CAR T cell therapy. (Sourced from: https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-First-Disclosures-and-New-Data-at-ASH-2022-Demonstrating-Commitment-to-Raising-Standards-in-Treatment-Through-Broad-Multiple-Myeloma-Portfolio/default.aspx)
Mechanisms of Action: CAR-T, GPRC5D
Novel Mechanism: Yes
Modality: Autologous CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P1 Multiple Myeloma results on 2025-12-06 for Atlacabtagene autoleucel
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P3 Multiple Myeloma results on 2025-06-01 for Atlacabtagene autoleucel
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P1 Multiple Myeloma results on 2024-12-09 for Atlacabtagene autoleucel
Highest Development Phases
Phase 3: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04674813 |
CC-95266-MM-001 | P1 |
Completed |
Multiple Myeloma |
2025-12-22 |
50% |
2026-02-10 |
|
NCT06121843 |
CA088-1005 | P1 |
Recruiting |
Multiple Myeloma |
2028-08-01 |
50% |
2026-02-19 |
Patient Enrollment|Primary Endpoints|Treatments |
jRCT2033240706 |
jRCT2033240706 | P2 |
Not yet recruiting |
Multiple Myeloma |
2031-09-30 |
|||
NCT06297226 |
QUINTESSENTIAL | P2 |
Recruiting |
Multiple Myeloma |
2027-06-30 |
12% |
2025-10-08 |
|
jRCT2053250007 |
jRCT2053250007 | P3 |
Not yet recruiting |
Multiple Myeloma |
2032-12-31 |
|||
2024-515279-37-00 |
CA088-1007 | P3 |
Recruiting |
Multiple Myeloma |
2032-06-21 |
2025-05-02 |
Treatments |
|
NCT06615479 |
QUINTESSENTIAL-2 | P3 |
Recruiting |
Multiple Myeloma |
2027-12-30 |
52% |
2025-08-27 |